Últimas noticias sobre Eli Lilly (NYSE:LLY) Bolsa

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Siegen,,North,Rhine,Westphalia,,,Germany,-,10,11,2023:

Biotech

Large Cap

News

Health Care

General

España investiga a Novo Nordisk por publicidad encubierta, mientras Reino Unido estudia factores genéticos en riesgos de medicamentos GLP-1.

Novo Nordisk bajo investigación:riesgos genéticos y posible publicidad encubierta en España

manufacturing PMI

Long Ideas

Trading Ideas

AAPL

NVDA

Apple, Nvidia, TSMC y otras grandes empresas están trayendo su producción de vuelta a EE. UU. en una nueva ola de relocalización.

Gigantes tecnológicos y fabricantes de EE. UU. apuestan por relocalizar su producción: ¿Vuelve el &#34;Made in USA&#34;?

Eli Lilly and Co.

Equities

Government

Markets

ABBV

AMGN

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

REGN

Trump quiere que las farmacéuticas vuelvan a EE. UU. ¿Cómo afectarán sus aranceles a las acciones del sector?

Trump presiona a farmacéuticas con aranceles para forzar regreso a EE. UU.

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Against a backdrop of regulatory scrutiny, with Spain investigating Novo Nordisk for alleged covert advertising of its popular weight-loss drugs, the U.K. is initiating research to determine if genetic factors impact the risk of acute pancreatitis associated with GLP-1 injections.
Yellow Card Biobank, a collaboration between the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England, will start investigating whether the risk of acute pancreatitis (inflamed pancreas) from GLP-1 injections for <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">weight loss and Type 2 diabetes</a> may be influenced by an individual&#8217;s genes.
The agency <a target="_blank" href="https://www.gov.uk/government/news/if-you-take-a-glp-1-medicine-and-have-been-hospitalised-by-acute-pancreatitis-the-yellow-card-biobank-wants-to-hear-from-you" rel="noreferrer noopener">said</a> in a statement on Thursday that although infrequent, acute pancreatitis has been reported with GLP-1 medicines.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46102213/us-adults-struggle-with-long-term-use-of-obesity-drugs-like-wegovy-data-shows" rel="noreferrer noopener">US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows</a>
Patients hospitalized with <a href="https://www.benzinga.com/general/biotech/23/10/35123873/novo-nordisks-weight-loss-drugs-like-wegovy-ozempic-may-pose-serious-stomach-risks-study-suggests" target="_blank" rel="noreferrer noopener">acute pancreatitis suspected </a>to be related to glucagon-like peptide-1 receptor agonists (GLP-1 medicines), such as Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic (semaglutide) and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro (Tirzepatide), are asked to report it to the MHRA&#8217;s&nbsp;Yellow Card scheme.
These medicines are sometimes referred to colloquially as &#8220;skinny jabs,&#8221; although they are licensed for both weight loss and Type 2 diabetes.&nbsp;
Healthcare professionals are also being asked to help recruit for the study by reporting Yellow Cards on behalf of patients experiencing acute pancreatitis while taking GLP-1 medicines.&nbsp;
When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to participate in the Biobank study.
This would involve providing further information and submitting a saliva or spit sample, which will be used to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genetic makeup.
Dr Alison Cave, MHRA Chief Safety Officer, said, &#8220;Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing. It is predicted that adverse drug reactions cost the NHS more than 2.2 billion pounds ($3.02 billion) a year in hospital stays alone.&#8221;
On June 19, Spain&#8217;s Ministry of Health, through the General Directorate of the Common Portfolio of Services of the National Health System (NHS) and Pharmacy, requested information from Novo Nordisk Pharma after detecting indications that one of its information portals may be <a href="https://www.bmj.com/content/389/bmj.r1319" target="_blank" rel="noreferrer noopener">violating</a> regulations regarding drug advertising.
The initiative follows a media report <a target="_blank" href="https://www.sanidad.gob.es/en/gabinete/notasPrensa.do?id=6699" rel="noreferrer noopener">about</a> a website, which redirects to another page called &#8220;Obesity without filters,&#8221; managed by the laboratory. It presents informative content related to the approach to obesity, including images expressly indicating that this is a Novo Nordisk initiative endorsed by various scientific societies.
The Ministry has formally requested that the company provide documentation regarding the endorsement declared by these scientific and professional organizations.
It has also drawn attention to another link on the website containing recommended questions for the doctor. Although no pharmacological treatment is explicitly mentioned, the Ministry believes that the content could constitute indirect advertising for prescription drugs, the public promotion of which is prohibited under current legislation.
Meanwhile, Novo Nordisk continues the expansion of patient access to Wegovy (semaglutide) injection 2.4 mg through a new collaboration with WeightWatchers beginning&nbsp;July 1, 2025.
WeightWatchers&nbsp;will <a target="_blank" href="https://www.prnewswire.com/news-releases/novo-nordisk-continues-efforts-to-support-patient-access-to-authentic-fda-approved-wegovy-and-prioritize-patient-safety-302492419.html" rel="noreferrer noopener">work</a> with&nbsp;CenterWell&nbsp;Pharmacy as the dispensing pharmacy managing prescription fulfillment and delivery for NovoCare Pharmacy.
Novo Nordisk said on Thursday that it is also introducing a new cash-offer price of&nbsp;$299, available through&nbsp;July 31, 2025.
This&nbsp;$299&nbsp;introductory price is available for self-paying patients new to the Wegovy&nbsp;savings offer or those who have not previously filled a prescription through NovoCare&nbsp;Pharmacy.
This builds on the previous&nbsp;$199&nbsp;Wegovy&nbsp;cash-offer patient price that expires on&nbsp;June 30, 2025.
Patients who redeemed the&nbsp;$199&nbsp;Wegovy&nbsp;savings offer&nbsp;between May 22 and June 30, 2025, will be eligible for the&nbsp;$299&nbsp;price on one fill&nbsp;between July 1 and July 31.
For subsequent months, self-paying patients will pay&nbsp;$499&nbsp;per month.
The company said in a press release that with all doses of FDA-approved Wegovy fully available nationwide, it is illegal under <a target="_blank" href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" rel="noreferrer noopener">U.S. compounding laws</a> to make or sell knockoff &#8220;semaglutide&#8221; drugs, with rare exceptions.&nbsp;
Price Action: NVO stock is up 1.77% at $68.90 during the premarket session at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46136734/rfk-jrs-cdc-panel-recommends-mercks-rsv-shot-for-infants" target="_blank" rel="noreferrer noopener">RFK Jr&#8217;s CDC Panel Recommends Merck&#8217;s RSV Shot For Infants</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs

<a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-updated-label-lillys-amyvid-florbetapir-f-18" title="https://investor.lilly.com/news-releases/news-release-details/fda-approves-updated-label-lillys-amyvid-florbetapir-f-18">https://investor.lilly.com/news-releases/news-release-details/fda-approves-updated-label-lillys-amyvid-florbetapir-f-18</a>

Ely Lilly Announces The U.S. FDA Approves Updated Label For Its Amyvid To Support Diagnosis Of Alzheimer's Disease In Patients

Although glucagon-like peptide-1 (GLP-1) agonists have shown promising results in reducing weight and cardiovascular risks, new data reveals that many U.S. adults struggle to stay on <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">long-term treatment</a>.
While newer obesity-indicated GLP-1 therapies, such as semaglutide and tirzepatide, are increasingly used, poor persistence rates threaten the clinical and economic benefits of these medications.
Novo Nordisk A/S' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide is the main input in Ozempic and Wegovy, and tirzepatide is a key ingredient in Eli Lilly &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro and Zepbound.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46076029/novos-india-move-could-reshape-the-weight-loss-drug-war-with-eli-lilly" rel="noreferrer noopener">Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly</a>
GLP-1 agonists have been linked to 10% to 20% weight loss in clinical trials, with some studies also showing reduced cardiovascular events in individuals without diabetes.
Yet, despite these benefits, long-term adherence remains a major hurdle. A 2023 real-world study by Prime Therapeutics found that just 27% of users remained adherent for one year, and only 15% persisted for two years. At three years, only 8.1% of users were still on treatment.
Even the best-performing drug, Wegovy, had a three-year persistence rate of just 14.3%.
The three-year analysis included 5,780 individuals continuously enrolled in a health plan after initiating GLP-1 treatment for obesity.
The group had a mean age of 46.7 years, and nearly 80% were women. Persistence rates varied widely by medication, from 14.3% with weekly semaglutide (Wegovy) to 2.5% with daily liraglutide (Victoza).
Over three years, only 12.5% of users met the standard for adherence based on medication possession, and more than one-third switched to a different GLP-1 therapy.
However, more recent <a target="_blank" href="https://www.primetherapeutics.com/w/prime-therapeutics-leading-research-shows-only-1-in-12-remain-on-a-glp-1-drug-for-obesity-at-three-years" rel="noreferrer noopener">data</a> suggests that persistence may be improving. In a separate year-over-year analysis involving 23,025 individuals initiating high-potency GLP-1s—Wegovy and Zepbound—one-year persistence rose from 33.2% in 2021 to 62.7% in 2024.
Tirzepatide (Zepbound), introduced in late 2023, had one-year persistence rates of over 62% in both 2023 and 2024.
This trend toward better short-term adherence is attributed to reduced supply shortages, improved dose escalation strategies, better side-effect management, and support programs.
Nonetheless, experts <a target="_blank" href="https://www.primetherapeutics.com/documents/d/primetherapeutics/prime-therapeutics_glp-1-therapy-to-treat-obesity-among-members-without-diabetes_three-year-persistence" rel="noreferrer noopener">caution</a> that poor long-term persistence among early adopters signals potential investment risk and limits the therapies' full clinical impact.
Further research is needed to understand why so many users discontinue treatment and whether newer approaches can sustain adherence over the long term.
Price Action: LLY stock is up 1.92% at $792.37, and NVO stock is down 5.03% at $67.17 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/46101643/did-the-fda-make-a-mistake-sareptas-elevidys-approval-under-scrutiny">Did The FDA Make A Mistake? Sarepta&#8217;s Elevidys Approval Under Scrutiny</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company&#8217;s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46091315/viking-therapeutics-announces-initiation-of-phase-3-obesity-clinical-program-with-glp-1gip-agonist" rel="noreferrer noopener">polypeptide (GIP) receptors</a>.
VK2375 is being developed in oral and subcutaneous formulations for metabolic <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">disorders such as obesity</a>.
The VANQUISH Phase 3 program includes two studies evaluating VK2735: one in adults with obesity and one in obese or overweight adults with type 2 diabetes.&nbsp;
Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/01/42827918/viking-therapeutics-structure-therapeutics-positioned-as-key-pharma-partners-for-weight-loss-products-analyst" target="_blank" rel="noreferrer noopener">Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst</a>
VANQUISH-1 study: The study will target enrollment of approximately 4,500 obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) adults with at least one weight-related co-morbid condition.
VANQUISH-2 study: The study will target enrollment of approximately 1,100 adults with type 2 diabetes who are obese or overweight. 
Participants in both trials will be randomized to one of four weekly treatment arms: VK2735 7.5 mg, VK2735 12.5 mg, VK2735 17.5 mg, and placebo, slightly higher than the currently approved Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound doses of 5 mg, 10 mg and 15 mg.
The trials&#8217; primary endpoint is the percent change in body weight from baseline for participants receiving VK2735 compared to placebo after 78 weeks of treatment.
Secondary and exploratory endpoints will evaluate additional safety and efficacy measures, including the percentage of patients who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction.&nbsp;
Each study will include an open-label extension, allowing participants to continue receiving treatment after the primary dosing period is completed.
In 2024, Viking announced topline results from the Phase 2 VENTURE study of subcutaneous VK2735 in obesity.
The VENTURE trial successfully achieved its primary and all secondary endpoints, with patients receiving VK2735 demonstrating clinically meaningful reductions in body weight compared with placebo.
Patients receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7%, and statistically significant reductions in mean body weight relative to placebo, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" rel="noreferrer noopener">ranging up to 13.1%</a>.
Differences compared to placebo were statistically significant for all doses starting at week one and were maintained throughout the study.
In addition, results from follow-up visits four and seven weeks after the last dose of VK2735 was administered showed that cohorts receiving VK2735 maintained the majority of their weight loss through the seven-week follow-up visit after administering the final dose.
VK2735 also demonstrated encouraging safety and tolerability in the VENTURE study, with most observed adverse events (AEs) being reported as mild or moderate.
Treatment and study discontinuation rates among VK2735 cohorts were well-balanced compared with placebo. Of gastrointestinal (GI) related AEs, 95% were reported as mild or moderate.
Why it Matters: William Blair notes some obesity experts said that insurance companies often won't cover certain &#8220;non-standard&#8221; Zepbound doses like 2.5 mg, 7.5 mg and 12.5 mg, even though these may be the best long-term doses for some patients.
While large academic hospitals with specialized reimbursement teams can usually work around this issue, smaller or community clinics may benefit from approving these in-between doses, as it could make treatment more accessible for more patients.
Analyst Andy Hsieh expects that 17.5 mg VK2735 could contribute to additional weight loss over 15 mg Zepbound and surmises there could be a potential ceiling effect when it comes to increasingly higher doses of Zepbound or VK2735.
&#8220;We continue to believe that Viking's obesity franchise offers a unique set of attractive qualities that will be viewed favorably in the lens of big pharma from an M&amp;A perspective&#8230;,&#8221; William Blair analyst wrote on Wednesday.
VKTX Price Action: VKTX stock is down 1% at $26.68 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46097698/bumble-is-breaking-up-with-30-staff-investors-swipe-right" target="_blank" rel="noreferrer noopener">Bumble Is &#8216;Breaking Up&#8217; With 30% Staff, Investors Swipe Right</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Analyst Ratings

Movers

VKTX

What's Going On With Viking Therapeutics Stock On Wednesday?

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has reportedly <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">launched its weight-loss</a> drug Wegovy (semaglutide) in India to compete with Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
In March this year, U.S. pharma giant Eli Lilly launched its popular weight loss drug Mounjaro (tirzepatide) in India. It is expected to have the second-largest population of overweight or <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">obese people by 2050</a>.
A Reuters report on Tuesday said that Wegovy, a weekly injection, will be available in pharmacies by the end of this month. It could take some market share away from Eli Lilly. Meanwhile, sales of Eli Lilly's drug Mounjaro rose 60% between April and May, the report highlighted, citing industry analysts.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern" rel="noreferrer noopener">Novo Nordisk&#8217;s Weight Loss Injection CagriSema Data Sparks Investor Concern</a>
Novo Nordisk told Reuters that Wegovy is available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses. The first three will be priced at 4,336 rupees ($50.7), and the monthly cost will be 17,345 rupees ($201.4), similar to Eli Lilly&#8217;s Mounjaro.
The Reuters report added that Wegovy&#8217;s 1.7 mg dose will be priced at 24,280 rupees ($281.90) and 2.4 mg at 26,015 rupees.
Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 Indian rupees ($50.86) for a 5 mg vial and 3,500 rupees for a 2.5 mg vial, its lowest dose, the company told Reuters. Its highest dose is 15 mg.
On Monday, Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for updating the Ozempic (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.
Following the <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916358" rel="noreferrer noopener">positive</a> opinion from the CHMP, Novo Nordisk expects the European Commission to implement the label update within approximately two months.
Novo Nordisk has also filed for a label expansion of Ozempic in the U.S., and a decision is expected in the last quarter of 2025.
Based on data from the SOUL trial, Novo Nordisk has also filed with the EMA and FDA for a label expansion for Rybelsus.
This could potentially make Rybelsus the first and only oral GLP-1 RA with proven cardiovascular (CV) benefits. A decision is also expected in the second half of 2025.
On Monday, the New England Journal of Medicine (NEJM) published results from Novo Nordisk&#8217;s phase 3 REDEFINE 1 trial of CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern" rel="noreferrer noopener">complication and without diabetes</a>.
Price Action: NVO stock is up 1.25% at $70.59 at last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46067629/hims-ceo-slams-novo-nordisk-for-anticompetitive-demands-after-ozempic-maker-abruptly-ends-partnership-we-refuse-to-be-strong-armed" target="_blank" rel="noreferrer noopener">Hims CEO Slams Novo Nordisk For &#8216;Anticompetitive Demands&#8217; After Ozempic Maker Abruptly Ends Partnership: &#8216;We Refuse To Be Strong-Armed&#8217;</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly

On Sunday, The New England Journal of Medicine (NEJM) published results from Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) <a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">phase 3 REDEFINE 1 trial</a> of CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">weight-related medical</a> complication and without diabetes.
CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme).
CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analog, cagrilintide. 
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/06/45927887/novo-nordisk-moves-amycretin-into-phase-3-trials-for-weight-management-becomes-europes-largest-company" target="_blank" rel="noreferrer noopener">Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe&#8217;s Largest Company</a>
<h2 class="wp-block-heading">REDEFINE 1 Trial</h2>
If all patients adhered to treatment, CagriSema <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916353" rel="noreferrer noopener">resulted</a> in a greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group.
When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved a statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group.
In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI &lt; 30 kg/m2) at the end of treatment, from a mean BMI of 38 kg/m2 at the start of treatment.
In the placebo group,10.2% reached that threshold at 68 weeks.
Select confirmatory secondary endpoints showed that if all participants adhered to treatment, 40.4% of those receiving CagriSema achieved a weight reduction of ≥25%.
Additionally, 23.1% lost ≥30% of their body weight.
When applying the treatment policy estimand, 34.7% of participants treated with CagriSema achieved ≥25% body-weight reduction, and 19.3% achieved ≥30%.
In a prespecified analysis of 252 participants, the relative reduction in fat and lean soft-tissue mass from baseline to week 68 was -35.7% (fat mass) and -14.4% (lean soft-tissue mass) for those treated with CagriSema versus –5.7% and –4.3% for the placebo group, respectively.
These data, along with the related <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44244966/novo-nordisks-combo-drug-cagrisema-shows-16-weight-reduction-in-second-phase-3-trial-stock-falls" rel="noreferrer noopener">phase 3 REDEFINE 2 study</a> conducted in adults with overweight or obesity and type 2 diabetes, were presented at the American Diabetes Association.
<h2 class="wp-block-heading">REDEFINE 2 Study</h2>
If all participants adhered to treatment, the estimated mean change in body weight from baseline to week 68 was –15.7% with CagriSema versus –3.1% with placebo.
When applying the treatment policy estimand, the estimated mean change in body weight from baseline to week 68 was –13.7% with CagriSema versus –3.4% with placebo.
A greater proportion of participants receiving CagriSema, compared with placebo, reduced their body weight by &gt;5% (83.6% vs. 30.8% of participants), ≥10% (65.6% vs. 10.3%), ≥15% (43.9% vs. 2.4%), and ≥20% (22.9% vs. 0.5%;)
The safety results from CagriSema in REDEFINE 2 were similar to those reported in the REDEFINE 1 trial.
Novo Nordisk initiated the REDEFINE 11 trial with the first patient visit in early June 2025. REDEFINE 11 will explore further weight loss potential and safety of CagriSema 2.4 mg / 2.4 mg through a longer trial duration and other protocol changes compared to REDEFINE 1 and 2.
<h2 class="wp-block-heading">Market Reaction</h2>
NVO experienced a decline of over 7% in premarket trading on Monday; the market&#8217;s reaction suggests that Novo Nordisk&#8217;s CagriSema has been perceived to have a less favorable side effect profile when compared to Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) orforglipron.
In Eli Lilly&#8217;s ACHIEVE-1 trial, the most common adverse events for participants treated with orforglipron (3 mg, 12 mg and 36 mg, respectively) were diarrhea (19%, 21% and 26%) vs. 9% with placebo, nausea (13%, 18% and 16%) vs. 2% with placebo, dyspepsia (11%, 20% and 15%) vs. 7% with placebo, constipation (8%, 17% and 14%) vs. 4% with placebo, and vomiting (5%, 7% and 14%) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46041936/lillys-oral-glp-1-orforglipron-showed-compelling-efficacy-and-a-safety-profile-consistent-with-inj" rel="noreferrer noopener">vs. 1% with placebo</a>.
In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs. 39.9% with placebo), including nausea (55% vs. 12.6 %), constipation (30.7% vs. 11.6%), vomiting (26.1% vs. 4.1%) and mainly were transient and mild-to-moderate in severity.
Adding to the investor concerns, William Blair analysts expressed disappointment, stating, &#8220;We had hoped that the amylin component could provide a higher magnitude of weight loss among patients living with type 2 diabetes. Unfortunately, the hypothesis did not come to fruition, and in our view, there is no evidence to suggest CagriSema should be prescribed over Zepbound in any subpopulation, based on the available data released to date.&#8221;
Analyst Andy Hsieh further elaborated that the &#8220;high frequency of adverse events could fuel uncertainty over the asset&#8217;s differentiation against approved (Zepbound) or late-stage investigational (retatrutide and MariTide) compounds.&#8221;
Price Action: At the last check on Monday, NVO stock was down 7.10% to $68.53 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46048974/eli-lillys-investigational-oral-pill-shows-weight-loss-benefits-with-lingering-side-effect-concerns">Eli Lilly&#8217;s Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns</a></li>
</ul>
Image via Shutterstock

Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Saturday announced detailed results from the ACHIEVE-1 Phase 3 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diet and exercise alone</a>.
The company released its topline data <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential" rel="noreferrer noopener">from the trial in April</a>.
At 40 weeks, all three doses (3 mg, 12 mg, 36 mg) of orforglipron achieved the primary endpoint of superior A1C reduction.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/46003836/eli-lillys-1-3-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst</a>
In addition, the 12 mg and 36 mg doses showed clinically meaningful and statistically significant reductions in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46041936/lillys-oral-glp-1-orforglipron-showed-compelling-efficacy-and-a-safety-profile-consistent-with-inj" rel="noreferrer noopener">body weight vs. placebo</a>.
In the study, orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks, lowering A1C by 1.3% to 1.6% from a baseline of 8.0% for the efficacy estimand.
In key secondary endpoints, up to 76.2% of participants taking orforglipron achieved the ADA treatment target A1C of &lt;7%, 66.0% achieved an A1C of ≤6.5%, and 25.8% achieved &lt;5.7%, defined as a normal A1C value.
Improvements in A1C were observed as early as four weeks and were accompanied by similar reductions in fasting serum glucose.
In another key secondary endpoint, participants taking the highest dose of orforglipron lost an average of 16.0 lbs (7.9%). 
While participants in ACHIEVE-1 did not appear to reach a weight plateau, longer-duration trials, such as the ATTAIN trials, will provide a comprehensive evaluation of the safety and efficacy of orforglipron for obesity.
While the tolerability profile was in line with the incretin class, William Blair highlights that at the highest dose, nausea, vomiting, and constipation did not appear to subside over time, in contrast with its peptide GLP-1 receptor agonist counterparts.
&#8220;We are less bullish about the prospects of orforglipron in this setting for two reasons: early plateauing and persistent side effects,&#8221; said analyst Andy Hsieh.
<h2 class="wp-block-heading">Once-Weekly Insulin Efsitora</h2>
In addition to the orforglipron data, Eli Lilly also shared promising results for its investigational once-weekly insulin, efsitora.
On Sunday, Eli Lilly announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin <a href="https://www.benzinga.com/pressreleases/25/06/n46043947/lillys-once-weekly-insulin-efsitora-alfa-demonstrated-a1c-reduction-and-a-safety-profile-consisten" target="_blank" rel="noreferrer noopener">and mealtime insulin, respectively</a>.
Eli Lilly released topline results from the QWINT-1 and QWINT-3 trials <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40731728/eli-lillys-once-weekly-insulin-shows-non-inferior-blood-sugar-reduction-vs-frequently-used-daily-" rel="noreferrer noopener">in September 2024</a>.
In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin.
In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand.
In the trial, efsitora was titrated to four fixed doses at four-week intervals, as needed for blood glucose control.
In QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec at week 26 for the efficacy estimand. In QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine.
Lilly plans to submit&nbsp;efsitora for adults with type 2 diabetes to global regulatory agencies by the end of this year.
In QWINT-1, efsitora resulted in approximately 40% fewer hypoglycemic events compared to insulin glargine, with estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure of 0.50 with efsitora vs. 0.88 with insulin glargine at 52 weeks. In QWINT-3, these rates were 0.84 with efsitora vs. 0.74 with insulin degludec at 78 weeks.
In QWINT-4, estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 6.6 with&nbsp;efsitora vs. 5.9 with insulin glargine at 26 weeks.
Across the three trials, efsitora demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for type 2 diabetes.
Price Action: LLY stock is trading lower by 0.19% to $761.25 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/46036868/obesity-drugs-help-with-weight-loss-but-are-adding-fat-elsewhere" target="_blank" rel="noreferrer noopener">Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere</a></li>
</ul>
Image via Shutterstock

Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns

<ul>
<li>Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing</li>
<li>Lilly plans to submit&nbsp;efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year</li>
</ul>

Reported Sunday, Lilly's Once-Weekly Insulin Efsitora Alfa Demonstrates Non-Inferior A1C Reduction To Daily Basal Insulin In Multiple Phase 3 Trials

The investigational once-daily pill&nbsp;lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes&nbsp;
In ACHIEVE-1, orforglipron also led to an average weight loss of 16.0 lbs (7.9%) at the highest dose by week 40 in a key secondary endpoint
The safety profile of orforglipron was consistent with the established GLP-1 class

Reported Saturday, Lilly's Once-Daily Oral GLP-1 Orforglipron Achieves Significant A1C And Weight Reduction In Phase 3 ACHIEVE-1 Trial Published In NEJM

A surge in demand for weight-loss and diabetes medications, paired with fears of incoming tariffs, has propelled Ireland to the center of a pharmaceutical trade boom with the U.S., dramatically widening the <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">bilateral trade imbalance</a>.
This year alone, $36 billion worth of hormone ingredients—essential for popular drugs like GLP-1 treatments and insulin analogs—have been flown from Ireland to the U.S., more than doubling last year&#8217;s total.
The Wall Street Journal <a target="_blank" href="https://www.wsj.com/health/pharma/how-weight-loss-drugs-blew-out-the-u-s-trade-deficit-2d8c668c" rel="noreferrer noopener">stated</a> that these pharmaceutical ingredients weighed 23,400 pounds, were highly concentrated, and shipped in temperature-controlled containers.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45998123/scholar-rocks-atrophy-drug-when-combined-with-eli-lillys-zepbound-shows-around-55-better-muscle-preservation-in-weight-loss-study" rel="noreferrer noopener">Scholar Rock&#8217;s Atrophy Drug When Combined With Eli Lilly&#8217;s Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study</a>
Nearly all were bound for Indiana, where Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), the maker of blockbuster drugs Zepbound and Mounjaro, is based.
The company began manufacturing these products in its Kinsale, Ireland facility last year and is now preparing to seek U.S. approval for a weight-<a target="_blank" href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" rel="noreferrer noopener">loss pill, orforglipron</a>.
This airlift of peptide and protein-based hormones, compounds that regulate appetite and metabolism, has played a key role in pushing Ireland to the second spot on U.S. goods-trade deficits, trailing only China.
In the first four months of 2025, the U.S. imported $71 billion in goods from Ireland, with hormone ingredients accounting for nearly half.
The rush stems from both commercial and geopolitical pressures. Former President Donald Trump&#8217;s shifting trade policies have triggered stockpiling by pharmaceutical companies racing to beat tariff deadlines.
A Section 232 investigation launched in April could lead to new levies on imported <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44847222/trump-administration-opens-probe-into-foreign-drug-imports-eyes-tariffs-under-national-security-law" rel="noreferrer noopener">drugs and active ingredients</a>.
The report added that Ireland, home to just 5.4 million people, is a hub for U.S. pharmaceutical manufacturing, partly due to its favorable tax structure.
Giants like AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) produce leading treatments such as Botox and Keytruda there.
Ireland&#8217;s central bank <a target="_blank" href="https://www.benzinga.com/markets/eurozone/25/06/46034817/us-multinationals-including-pharma-firms-power-over-5-of-eurozone-economy-ecb-says" rel="noreferrer noopener">attributed</a> a nearly 10% GDP growth in Q1 to soaring pharma exports.
However, the trade imbalance has drawn scrutiny. Ireland was recently added to the U.S. Treasury Department&#8217;s currency manipulation watchlist. Dan O&#8217;Brien of Dublin&#8217;s Institute of International and European Affairs said the attention is &#8220;definitely not welcome,&#8221; especially as Ireland alone accounts for a large share of the U.S.-EU deficit.
The logistical strain is also evident. Pharma shipments from Ireland to the U.S. more than doubled in March and April, with logistics firms working overtime. Lufthansa Cargo and Kuehne + Nagel reported increased volumes, although activity began to slow in April as U.S. warehouses filled up.
As the White House pushes to onshore drug manufacturing, companies like Lilly and Merck are ramping up domestic investments, aiming to reduce reliance on foreign supply chains amid regulatory uncertainty.
Price Action: LLY stock is down 2.55% at $765.05&nbsp;at the last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/46003836/eli-lillys-1-3-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst</a></li>
</ul>
Photo by M7kk via Shutterstock

Media

Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere

With the S&amp;P 500 Index meandering along at a 1.69% year-to-date return, you can't fault investors looking for some juice out of their portfolios at the mid-point of 2025.
One way to increase your portfolio&#8217;s profit potential is to look for undervalued stocks that aren't generating headlines or creating buzz on Reddit but are showing signs of popping in the second half of 2025.
Undervalued stocks are securities that trade below their assumed value.
That low price may be justified, as a low stock price doesn&#8217;t guarantee a future rebound if the underlying business doesn&#8217;t improve.
"Yet companies with strong net margins, low earnings multiples (relative to price), and clean balance sheets are more likely to be resilient and do well through downturns," said Dan Buckley, chief analyst at DayTrading.com
Buckley points to one underdog stock that made it big: Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>).
"Look at Advanced Micro Devices, which for years was a distant second to Intel in the semiconductor industry," he said. "10 years ago, it commonly traded at around a market cap of only $3 billion, and now it's over $200 billion."
Buckley noted that AMD&#8217;s resurgence was driven by a strategic pivot under CEO Lisa Su. The company focused on high-performance computing and consistently delivered innovative, powerful chips that won significant market share.
"This turnaround shows how strong leadership and a clear, forward-looking strategy can transform an underperforming company into a market leader," Buckley said.
<h2 class="wp-block-heading">Matt Maley's Strategy for Navigating Global Risks and Sector Shifts—Live This Wednesday</h2>
The market is volatile, and global forces are in motion. Geopolitical risks, inflation, and sector rotations are reshaping market leadership. Join Matt Maley this Wednesday, June 25 at 6 PM ET as he reveals his strategy for navigating these shifts—including which sectors he's targeting and how he's adjusting his portfolio. This live session will give you the real-time strategy you need to trade smart into July. Register <a href="https://events2.benzinga.com/matt-maley-webinar-wed-june25-2025-registration/?utm_campaign=webinar062525&amp;utm_adType=sponsorad&amp;utm_ad=RD062325">HERE</a> for free.
<h2 class="wp-block-heading">3 Potential Underdog Stocks for 2025</h2>
Benzinga canvassed several market mavens this week and asked them for potential powerhouse underdog stocks waiting for their chance to howl – here's what they had to say.
<h3 class="wp-block-heading">Centene</h3>
Year-to-Date Performance: -8.96% as of June 20, 2025
Benzinga Value Rating: 73.05
Brian Krawez, CFA and president of Scharf Investments, LLC, likes Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), a healthcare enterprise company.
"CNC is one of our favorite under-the-radar stocks," Krawez said. 
Centene is a health insurance managed care organization (MCO) focusing on the Medicaid, Medicare, and ACA Marketplace programs. Founded in 1984, Centene is the top player in Medicaid and Marketplace and now has 28 million members across the US.
"It collects premiums from the health plan sponsors and contracts with the providers to pay for care services that its members use," he noted.
Over the past 10 years, CNC has grown revenue by +26% CAGR and adjusted accordingly. EPS stands at plus-20% CAGR, driven by a steady Medicaid program expansion. "Recently, earnings growth has slowed due to post-COVID Medicaid redetermination and elevated member care utilization rates," Krawez added. "But as the states update the price reimbursement to reflect this increased member utilization level, we expect CNC to return to a more normalized margin."
Krawez believes that in the long haul, Medicaid will continue to grow at its historical rate of 5%-7 %, which would be good news for CNC shareholders. "It's the largest player in the space and should continue to leverage its scale and expertise in steering care to the most efficient place and grow earnings double-digits," he said. &#8220;In addition, management is a good capital allocator and has been aggressively buying back stock, signaling their confidence in the company's prospects."
<h3 class="wp-block-heading">Wendy's</h3>
Year-to-Date Performance: -30.49%
Benzinga Value Rating: 40.88
Buckley's favorite underdog stock is the iconic fast-food chain, Wendy&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>).
"Wendy's has strong brand recognition, a quality P/E ratio (12x) in an otherwise relatively expensive market, and consistent dividend payments (around a 5% yield)," Buckley said. "Yet it's currently overshadowed by current market pressures."
Additionally, the company&#8217;s digital growth and international expansion represent "compelling long-term value" that the market might be underappreciating, he added. "Many consumers are also highly value-conscious, which can support Wendy&#8217;s growth as it competes on affordability." 
Pivoting to a more efficient digital operation should help Wendy&#8217;s, too.
"While the fast-food industry faces challenges with reduced foot traffic, Wendy&#8217;s focus on meal deals and growing its digital and delivery platforms caters directly to current consumer preferences for convenience and value," he added.
<h3 class="wp-block-heading">Eli Lilly</h3>
Year-to-Date Performance: 1.69%
Benzinga Quality Rating: 89.63
Chad Harmer, chief investment officer, founder, and financial planner at Harmer Wealth Management Corp. favors Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) as its underdog play in 2025.
"Major advancements in Eli's Obesity and Diabetes drugs like Mounjaro set the company up incredibly well for growth in the current market," Harmer said. "Moving forward, Eli is incredibly well-positioned to benefit from the aging population with Alzheimer&#8217;s therapies like Donanemab, bone health and osteoporosis treatments like Forteo, and an expanded pipeline in autoimmune and inflammatory diseases, all conditions prevalent in older age groups."
Harmer says, like with all of the above stocks, investors have to tread cautiously when vetting underdog stocks.
"Watch out for the ‘Value Trap,&#8217;" he added. "Stocks that seem cheap or undervalued need to be carefully investigated to ensure business fundamentals, management, and growth projections remain strong."
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

3 'Underdog Stocks' For The Rest Of 2025

The U.S. Food and Drug Administration (FDA) on Wednesday initiated <a href="https://www.fda.gov/news-events/press-announcements/fda-halts-new-clinical-trials-export-americans-cells-foreign-labs-hostile-countries-genetic">an immediate review</a> of clinical trials that involved sending Americans&#8217; living cells to China and other foreign adversaries for genetic engineering and subsequent infusion back into U.S. patients, sometimes <a href="https://www.benzinga.com/general/health-care">without their knowledge or consent</a>.
The <a target="_blank" href="https://www.nih.gov/news-events/news-releases/fda-halts-new-clinical-trials-export-americans-cells-foreign-labs-hostile-countries-genetic-engineering" rel="noreferrer noopener">move</a> comes amid growing concern over the security and ethics of cross-border biomedical research and the handling of sensitive genetic data.
Mounting evidence has shown that some clinical trials failed to inform participants that their biological samples would be transferred abroad, raising red flags about consent and potential misuse of genetic information by foreign governments.
Also Read: <a href="https://www.benzinga.com/news/fda/25/06/45982666/fda-introduces-tumor-board-style-reviews-for-faster-drug-decisions" target="_blank" rel="noreferrer noopener">FDA Introduces Tumor Board-Style Reviews For Faster Drug Decisions</a>
The practice became possible after the Biden Administration approved a sweeping exemption in late 2024, enabling U.S. companies to export biological samples for processing abroad, even in trials regulated by the FDA.
While the original intent of a 2024 data security rule was to limit data transfers to countries of concern, the exemption, implemented in April 2025, allowed exceptions even for companies partially owned or influenced by the Chinese Communist Party.
FDA Commissioner Dr. Marty Makary criticized the policy, &#8220;The previous administration turned a blind eye and allowed American DNA to be sent abroad, often without the knowledge or understanding of trial participants.&#8221; He emphasized the need to protect patient privacy and restore confidence in U.S. biomedical research.
As part of its response, the FDA will now require companies involved in such trials to prove full transparency, obtain ethical consent, and ensure domestic processing of biological material. New trials failing to meet these standards will not be allowed to proceed.
The agency is coordinating closely with the National Institutes of Health (NIH) to examine federally funded research for any links to the exemption.
NIH Director Dr. Jay Bhattacharya confirmed the agency is conducting a portfolio-wide review to assess whether any NIH-supported trials were affected.
&#8220;In light of the FDA&#8217;s actions and new information surrounding the Biden Administration&#8217;s egregious policies, the National Institutes of Health is actively reviewing its entire research portfolio to determine whether any federally funded clinical trials utilized the exemption issued under the Biden Administration that allowed American biological materials to be sent abroad for genetic modification, particularly to entities operating in countries of concern,&#8221; Bhattacharya said in a statement on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45326322/trump-appointed-martin-makary-targets-faster-drug-approvals-with-fda-artificial-intelligence-overhaul" target="_blank" rel="noreferrer noopener">Trump Appointed Martin Makary Targets Faster Drug Approvals With FDA Artificial Intelligence Overhaul</a></li>
</ul>
Photo by Tada Images via Shutterstock

CRBU

CRSP

NTLA

SANA

VRTX

FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed 13 unusual trades.
Delving into the details, we found 23% of traders were bullish, while 15% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $609,596, and 4 were calls, valued at $150,651.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $900.0 for Eli Lilly over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $300.0 to $900.0 in the last 30 days. 
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750428104_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$14.75</td>
<td>$10.8</td>
<td>$12.72</td>
<td>$775.00</td>
<td>$236.8K</td>
<td>686</td>
<td align="right">379</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$25.0</td>
<td>$19.9</td>
<td>$22.63</td>
<td>$780.00</td>
<td>$83.0K</td>
<td>1.3K</td>
<td align="right">553</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$127.65</td>
<td>$122.15</td>
<td>$124.94</td>
<td>$900.00</td>
<td>$74.9K</td>
<td>196</td>
<td align="right">7</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$31.75</td>
<td>$30.55</td>
<td>$30.55</td>
<td>$760.00</td>
<td>$61.1K</td>
<td>364</td>
<td align="right">38</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$482.15</td>
<td>$475.1</td>
<td>$478.61</td>
<td>$300.00</td>
<td>$47.8K</td>
<td>53</td>
<td align="right">1</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>Currently trading with a volume of 1,003,032, the LLY's price is down by -3.48%, now at $757.73. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 48 days.</li>
</ul>
<h3>Expert Opinions on Eli Lilly</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $936.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Guggenheim has revised its rating downward to Buy, adjusting the price target to $936. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Looking At Eli Lilly's Recent Unusual Options Activity

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $943.0, a high estimate of $1124.00, and a low estimate of $700.00. This current average represents a 8.7% decrease from the previous average price target of $1032.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1750428075_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Eli Lilly is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$936.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1050.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Rajesh Kumar</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Reduce</td>
<td>$700.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$975.00</td>
<td>-</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$928.00</td>
<td>$973.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1124.00</td>
<td>$1146.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$888.00</td>
<td>$892.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Eli Lilly. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Eli Lilly compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Eli Lilly's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Eli Lilly's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LLY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Eli Lilly analyst ratings.</a>
<h2>Discovering Eli Lilly: A Closer Look</h2>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Eli Lilly showcased positive performance, achieving a revenue growth rate of 45.17% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Eli Lilly's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.68%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Eli Lilly's ROE stands out, surpassing industry averages. With an impressive ROE of 18.42%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Eli Lilly's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.28% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Eli Lilly's debt-to-equity ratio surpasses industry norms, standing at 2.44. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 7 Analyst Projections For Eli Lilly

Guggenheim analyst Seamus Fernandez reiterates Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and maintains $936 price target.

Price Target

Reiteration

Guggenheim Reiterates Buy on Eli Lilly, Maintains $936 Price Target

On Tuesday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) agreed to acquire Verve Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>), a Boston-based clinical-stage company developing genetic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45968442/lilly-to-acquire-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovasc" rel="noreferrer noopener">medicines for cardiovascular disease</a>.
Lilly offered to purchase Verve for $10.50 per share in cash, an aggregate of approximately $1.0 billion, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash, an aggregate of up to <a target="_blank" href="https://www.benzinga.com/m-a/25/06/45970361/eli-lilly-expands-into-gene-editing-with-verve-therapeutics-acquisition" rel="noreferrer noopener">approximately $1.3 billion)</a>.
The transaction is expected to close in the&nbsp;third quarter of 2025. The purchase price payable at closing represents a premium of approximately 113% to the 30-day volume-weighted average trading price of Verve&#8217;s common stock ended on June 16, 2025, the last trading day before the deal announcement.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy" rel="noreferrer noopener">Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy</a>
The proposed acquisition of Verve Therapeutics by Eli Lilly is eliciting positive reactions from analysts, who see it as a crucial endorsement for the broader development-stage genetic medicines market.
Despite downgrading Verve to Neutral on Wednesday, HC Wainwright stated the offer provides &#8220;important validation&#8221; for a sector that has faced significant headwinds.
William Blair, which <a target="_blank" href="https://www.benzinga.com/quote/VERV/analyst-ratings" rel="noreferrer noopener">downgraded Verve to Market Perform</a> on Tuesday, similarly believes the deal is advantageous for Verve shareholders and aligns with Lilly&#8217;s existing pipeline exposure.
HC Wainwright&#8217;s Mitchell Kapoor underscored the acquisition&#8217;s importance in validating gene editing for &#8220;mass markets&#8221; such as cardiovascular conditions, an area of interest for other companies as well.
Kapoor also suggested Lilly&#8217;s substantial market value and strong cash flow, largely driven by its leadership in weight-loss drugs, would deter serious competing bids for Verve.
William Blair&#8217;s Myles Minter concurred that while a bargain for Eli Lilly, the 115% premium still represents a &#8220;win&#8221; for Verve shareholders and the gene editing space, which has been under considerable macro and funding pressure.
Both analysts see the acquisition of Verve as a substantial positive for multiple gene editing stocks, including CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), Intellia Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), Editas Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), Metagenomi Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>), and Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>).
Price Action: LLY stock is trading lower by 0.91% to $784.02, and VERV stock is down 1.98% at $11.16 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45655674/rocket-pharmas-gene-therapy-future-clouded-by-regulatory-uncertainty" target="_blank" rel="noreferrer noopener">Rocket Pharma&#8217;s Gene Therapy Future Clouded By Regulatory Uncertainty</a></li>
</ul>
Image via Shutterstock

Downgrades

BEAM

EDIT

VERV

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

Scholar Rock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-<a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">induced weight loss</a>.
Tirzepatide is an active ingredient in Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) widely used Mounjaro and Zepbound for diabetes and weight loss, respectively.
The trial demonstrated that 30% of the total weight loss with tirzepatide alone was <a href="https://www.benzinga.com/pressreleases/25/06/b45991772/scholar-rock-reports-positive-phase-2-embraze-trial-results-demonstrating-statistically-significan" target="_blank" rel="noreferrer noopener">due to lean mass loss</a>.
Apitegromab therapy (10 mg/kg) with tripeptide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% (p=0.001) of lean mass compared to tripeptide alone, leading to higher-quality weight loss.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44359926/scholar-rock-stock-jumps-on-additional-data-from-pivotal-trial-of-muscular-dystrophy-treatment" rel="noreferrer noopener">Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment</a>
The study showed that 30.2% of the total weight loss with tirzepatide, the ingredient in Zepbound, was due to lean mass loss.
According to 24-week data, adding 10 mg/kg apitegromab therapy to the tripeptide regimen halved the proportion of lean mass lost to 14.6%.
The company described the apitegromab-tirzepatide combo as "higher quality of weight loss." Specifically, these patients lost 85% and 15% of their fat and lean mass, respectively, while the ratio for the&nbsp;tirzepatide-placebo cohort was 70% and 30%.
Regarding total weight loss, patients on apitegromab-tirzepatide saw their weight drop by 12.3% compared to 13.4% for those on tirzepatide-placebo.
Apitegromab with tirzepatide was generally well tolerated by participants.
Earlier in June, Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)&nbsp;released interim results from the ongoing Phase 2 COURAGE trial investigating combinations of&nbsp;Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy (semaglutide) (GLP-1&nbsp;receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">(anti-activin A) for obesity</a>.
The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass.
Last week, Juvena Therapeutics Inc. announced global licensing and&nbsp;multi-target research collaboration&nbsp;with&nbsp;Eli Lilly. The two companies aim to develop and commercialize drug candidates that improve&nbsp;<a href="https://www.benzinga.com/news/health-care/25/06/45887444/eli-lilly-inks-pact-with-juvena-therapeutics-to-develop-muscle-boosting-drugs" target="_blank" rel="noreferrer noopener">muscle health and body composition</a>.
Price Action: SRRK stock is up 18% at $36.77 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45947852/eli-lilly-launches-flat-pricing-for-zepbound-capping-monthly-cost-at-499" target="_blank" rel="noreferrer noopener">Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499</a></li>
</ul>
Photo: Shutterstock

SRRK

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

Healthcare stocks are trailing the broader market by margins not seen since 2008, as tumbling pharma giants and a stampede toward tech and AI names have left the sector <a href="https://www.benzinga.com/markets">deeply out of interest.</a>
The Healthcare Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) now trades at just 0.2234 shares of the S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), its weakest relative value in more than a decade. In 2015, that ratio was 0.35, making today&#8217;s level a 40% drop in comparative value.
In May 2025, healthcare lagged the S&amp;P 500 by 11.2%, the worst single-month relative performance since records began. Versus the red-hot tech sector, the gap is even more extreme — at levels last seen in February 2000.
Have we been here before? Yes, and history suggests this kind of extreme undervaluation often triggers powerful reversals.
<h3 class="wp-block-heading">The Last Time Healthcare Was This Unloved Was In 2008&#8230;</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="528" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18082457/image-283-1024x528.png" alt="" class="wp-image-953798" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18082457/image-283-1024x528.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18082457/image-283-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18082457/image-283-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18082457/image-283-1536x792.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18082457/image-283-2048x1056.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Chart: TradingView
<h3 class="wp-block-heading">&#8230;When A Monster Rally Followed</h3>
After similar dislocations in May 2008 and October/November 2001, healthcare stocks sharply outpaced the broader market. 
From November 2001 to September 2002, the sector outperformed the S&amp;P 500 by 41%. From June 2008 to February 2009, it beat the market by a similar 40%.
<ul class="wp-block-list">
<li>Read More: <a href="https://www.benzinga.com/markets/guidance/25/06/45928561/gold-biggest-boom-in-decades-and-investors-are-still-missing-out">Gold&#8217;s Biggest Boom In Decades—And Investors Are Still Missing Out</a></li>
</ul>
When compared to tech stocks, the comeback is even more dramatic. 
Between March 2000 and September 2002, healthcare outperformed the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) by a staggering 390% as the dot-com bubble burst. 
These episodes followed the same pattern: investors often chased growth stocks until valuations became extreme. 
Healthcare, seen as a comparatively safer sector, then spiked as capital rotated back to battered value and defensive names.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="528" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18085730/image-288-1024x528.png" alt="" class="wp-image-953845" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18085730/image-288-1024x528.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18085730/image-288-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18085730/image-288-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18085730/image-288-1536x792.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/18085730/image-288-2048x1056.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">What's Triggering The Current Healthcare Slump?</h3>
Big pharma and healthcare insurers are dragging the whole sector lower. UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is down 40% year to date, its second-worst year since 1987.
Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) fell 18% in May, its steepest monthly drop since February 2009. 
Meanwhile, Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) has logged nine straight months of declines — a feat unmatched since the company went public in 1970.
<h3 class="wp-block-heading">Are Healthcare Stocks A Buy Right Now?</h3>
Wall Street analysts are optimistic that the sector might soon head towards a turnaround.
Of the 60 companies in the Healthcare Select Sector SPDR Fund, 59 have average 12-month analyst price targets above current market prices. The sector's weighted average upside stands at 17%.
For key players in the sector, Eli Lilly has a median analyst target that&#8217;s 22% above its current share price. UnitedHealth Group is expected to rise by 18%, while Merck &amp; Co. is forecasted 27% higher the next 12 months.
More traditional valuation metrics also support the bullish case. The sector trades at a forward price-to-earnings ratio of 21, well below the 30 for the S&amp;P 500 — highlighting just how steep the current discount is.
Read now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45974992/everyone-now-hates-the-dollar-is-that-the-ultimate-buy-signal">Everyone Now Hates The Dollar—Is That The Ultimate Buy Signal? </a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Tech

ETFs

Nobody Wants To Touch Healthcare Stocks Now – That Might Be A Big Mistake

Weight Loss drug maker Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has agreed to acquire Verve Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>), a Boston-based clinical-stage company developing genetic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45968442/lilly-to-acquire-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovasc" rel="noreferrer noopener">medicines for cardiovascular disease</a>.
Verve&#8217;s lead program (VERVE-102) is a potential first-in-class in vivo gene editing medicine targeting PCSK9, a gene linked to <a href="https://www.benzinga.com/general/health-care">cholesterol levels and cardiovascular health</a>.
The treatment may be applicable for people who have heterozygous familial hypercholesterolemia (HeFH), a subset of ASCVD that affects 1 in 250 people in the general population, as well as certain patients with premature coronary artery disease (CAD).
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/45947852/eli-lilly-launches-flat-pricing-for-zepbound-capping-monthly-cost-at-499" target="_blank" rel="noreferrer noopener">Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499</a>
VERVE-102 is being evaluated in a Phase 1b clinical trial study and has been granted Fast Track designation by the U.S. Food and Drug Administration.
In April, Verve Therapeutics released initial data from the Heart-2 Phase <a target="_blank" href="https://www.benzinga.com/25/04/44793762/verve-therapeutics-touts-positive-data-from-gene-editing-medicine-to-lower-cholesterol-after-single-dose" rel="noreferrer noopener">1b trial of VERVE-102</a>.
VERVE-102 was well-tolerated among 14 participants across three dose levels. No treatment-related serious adverse events (SAEs) and no clinically significant laboratory abnormalities were observed.
A single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 protein (regulates cholesterol metabolism) levels and LDL-C, with a mean reduction in blood LDL-C of 53% and a maximum LDL-C reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort.
Lilly has offered to purchase Verve for $10.50 per share in cash, an aggregate of approximately $1.0 billion, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash, an aggregate of up to approximately $1.3 billion).
CVR holders would become entitled to receive the contingent payment upon the first patient being dosed with VERVE-102 for ASCVD in a U.S. Phase 3 trial on or before the tenth anniversary of closing or termination of the CVR.
The transaction is expected to close in the&nbsp;third quarter of 2025.
The purchase price payable at closing represents a premium of approximately 113% to the 30-day volume-weighted average trading price of Verve&#8217;s common stock ended on June 16, 2025, the last trading day before the deal announcement.
Price Action: LLY stock is down 0.89% at $800.42, and VERV stock is up 75.9% at $11.03 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45263363/crispr-therapeutics-data-provides-promising-balance-rfk-jr-appointee" target="_blank" rel="noreferrer noopener">CRISPR Therapeutics&#8217; Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst</a></li>
</ul>
Image via Shutterstock

Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition

<ul>
<li>Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease</li>
<li>Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise</li>
</ul>

Eli Lilly Agrees To Acquire Verve Therapeutics For $10.50/Share In Cash (An Aggregate Of Approximately $1B) Plus One Contingent Value Right Of Up To An Additional $3.00 Per Share, For A Total Potential Consideration Of Up To $13.50 Per Share (An Aggregate Of Up To Approximately $1.3B)

Press Releases

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Dividends

Lilly declares third-quarter 2025 dividend

Small Cap

New AI Rollouts Signal Shift From Hype to Healthcare Reality

AVAI

PLTR

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Guggenheim

HSBC

Cantor Fitzgerald

Morgan Stanley

Untitled design - 2025-03-31T165341.547

TNXP

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2025-02-24 at 11.35.34 PM

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2024-11-20 at 6.30.30 PM

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Comments

Eli Lilly

Noticias

Últimas noticias sobre Eli Lilly (NYSE:LLY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL